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Abstract: Inﬂ  ammation of the lower airways is a central feature of chronic obstructive 
pulmonary disease (COPD). Inﬂ  ammatory responses are associated with an increased expression 
of a cascade of proteins including cytokines, chemokines, growth factors, enzymes, adhesion 
molecules and receptors. In most cases the increased expression of these proteins is the result 
of enhanced gene transcription: many of these genes are not expressed in normal cells under 
resting conditions but they are induced in the inﬂ  ammatory process in a cell-speciﬁ  c manner. 
Transcription factors regulate the expression of many pro-inﬂ  ammatory genes and play a key 
role in the pathogenesis of airway inﬂ  ammation.
Many studies have suggested a role for viral infections as a causative agent of COPD 
exacerbations. In this review we will focus our attention on the relationship between common 
respiratory viral infections and the molecular and inﬂ  ammatory mechanisms that lead to COPD 
exacerbation.
Introduction
Many epidemiological and clinical studies have suggested a role for respiratory viral 
infections in the natural history of chronic obstructive pulmonary disease (COPD), particu-
larly during their exacerbations highlighting the need for development of effective vaccines 
and/or treatment for these viruses. The precise cellular and molecular mechanisms underly-
ing these events are still largely unknown (Caramori et al 2006; Mallia et al 2007).
Lower airways inﬂ  ammation is a central feature of many lung diseases, including 
COPD. Although the speciﬁ  c characteristics of the inﬂ  ammatory responses and the site 
of inﬂ  ammation differ between one disease to another, they always involve recruit-
ment and activation of inﬂ  ammatory cells and changes in structural cells of the lung. 
Inﬂ  ammatory responses are associated with an increased expression of a cascade of 
proteins that includes cytokines, chemokines, growth factors, enzymes, adhesion mol-
ecules and receptors. In most cases the increased expression of these proteins is the 
result of enhanced gene transcription: many of the genes are not expressed in normal 
cells under resting conditions but they are induced in the inﬂ  ammatory process in a 
cell-speciﬁ  c manner. Transcription factors regulate the expression of many genes, 
including inﬂ  ammatory genes and play a key role in the pathogenesis of respiratory 
inﬂ  ammatory diseases, including COPD (Caramori et al 2004).
In this review we will provide an overview of the relationship between respiratory 
virus infection and the molecular mechanisms involved in the activation of airway 
inﬂ  ammation in COPD exacerbations.
Clinical impact of viral infections in COPD
COPD is a disease state characterized by airﬂ  ow obstruction that is not fully reversible. 
The airﬂ  ow obstruction is usually both progressive and associated with an abnormal International Journal of COPD 2007:2(4) 478
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inﬂ  ammatory response of the lung to noxious particles or gases. 
The main cause of COPD is cigarette smoking (GOLD 2006).
Chronic obstructive pulmonary disease (COPD) is 
the fourth leading cause of mortality worldwide (GOLD 
2006). Costs of COPD are mainly related to exacerbations 
requiring hospitalization (Sullivan et al 2000). In addition 
to their enormous acute morbidity, mortality and cost, 
exacerbations are also associated with major reductions in 
long term quality of life and lung function (Seemungal et al 
1998; Donaldson et al 2002).
Despite the clinical and economic importance of severe 
COPD exacerbations, their etiology and mechanisms are 
poorly understood.
Both bacterial (Sethi and Murphy 2001; White et al 2003) 
and viral infections (Seemungal et al 2000, 2001; Aaron et al 
2001; Rohde et al 2003; Wedzicha 2004; Beckham et al 2005; 
Papi et al 2006) have been detected at increased frequencies 
during COPD exacerbations. The most frequently respiratory 
viruses involved in the etiology of COPD exacerbations are 
represented by rhinoviruses, inﬂ  uenza viruses, coronaviruses, 
and respiratory syncytial virus (RSV). More rarely parainﬂ  u-
enza viruses and human metapneumoviruses (HMPV) have 
also been identiﬁ  ed (Rohde et al 2003; Hamelin et al 2005; 
Falsey et al 2006; Papi et al 2006).
A recent study has recently addressed the relative 
importance of viral versus bacterial infections in the etiology 
of severe (hospitalized) COPD exacerbations (Papi et al 
2006). Viral and/or bacterial infection was detected in 78% 
of COPD exacerbations (29.7% bacterial, 23.3% viral, 25% 
viral/bacterial co-infection). Infectious exacerbations had 
longer hospitalizations and greater impairment of several 
measures of lung function than non-infectious exacerbations. 
Importantly, exacerbations with co-infection had more 
marked lung function impairment and longer hospitalizations. 
Similarly, when COPD exacerbations not requiring hospital-
ization were evaluated, a greater lung function fall was docu-
mented in those patients where both bacterial infection and 
cold symptoms were present simultaneously (Wilkinson et al 
2006). This data suggests that bacterial and viral infections 
could synergistically cooperate to increase severity of the 
exacerbations. Whether viral infections can lead to bacte-
riological exacerbation (of previously colonizing bacteria) 
is still an open question that deserves properly designed 
longitudinal studies.
Determining the etiology of exacerbations will inform 
appropriate antibiotic and antiviral therapy. Antibiotic therapy 
is already widely used, but not always appropriately, in the 
treatment of COPD exacerbations (GOLD 2006). Indeed, 
a recent meta-analysis supports antibiotics only for those 
patients with COPD exacerbations with increased cough and 
sputum purulence who are moderately or severely ill. Analysis 
restricted to community-based studies did not ﬁ  nd any dif-
ferences between antibiotic and placebo (Ram et al 2006). In 
asthma, recent study showed a signiﬁ  cation reduction of symp-
toms at exacerbations in those patients receiving telithromycin 
as compared to placebo. Given that no relationship between 
bacteriologic status and the response to study treatment was 
found, the mechanisms of such a beneﬁ  t remain unclear 
(Johnston et al 2006). Therefore, (i) there is an urgent need 
to develop simple clinical or biological markers to identify 
those patients at highest risk of bacterial infection and who 
will beneﬁ  t most from antibiotic therapy, (ii) further studies 
are needed to evaluate whether novel class of antibiotics can 
be more effective in the treatment of COPD exacerbations.
Antiviral therapy, and in particular anti-rhinovirus 
therapy, is a “still theoretically” relevant therapeutic option 
since two thirds of exacerbations are associated with viral 
infections (Seemungal 2001). Indeed, so far no study has 
investigated whether currently available antiviral treatment 
can reduce viral induced COPD exacerbations. The use of 
anti-inﬂ  uenza neuraminidase inhibitors in COPD exacerba-
tions during inﬂ  uenza epidemic appears appropriate in non 
vaccinated patients and may reduce the number of hospital-
izations (Lalezari et al 2001; Cooper et al 2003; Kaiser et al 
2003), though further controlled clinical trials are needed to 
conﬁ  rm therapeutic beneﬁ  t.
Susceptibility to virus infections
in COPD patients
Viral infections are the most frequent cause of COPD exac-
erbation. Whether COPD patients are more susceptible to 
virus infection as compared to normal subjects is still debated. 
A recent study documented that patients with frequent COPD 
exacerbation have more frequent episodes of naturally occur-
ring colds as compared to patients with infrequent exacerba-
tions (Hurst et al 2005). These results suggest that COPD 
subjects with frequent exacerbations may represent a sub-
group particularly susceptible to viral infections. Thus, while 
there is solid evidence of impaired innate (Wark et al 2005; 
Contoli et al 2006) and possibly acquired (Gern et al 2000; 
Papadopoulos et al 2002) immune responses to viral infection 
in asthmatic patients, it is not yet clear whether COPD patients 
have increased susceptibility to viral infections. Intriguingly 
patients experiencing frequent colds had a signiﬁ  cantly higher 
exposure to cigarette smoke (Hurst 2005). Recently, using 
a mouse model of cigarette smoke exposure, it has been International Journal of COPD 2007:2(4) 479
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demonstrated that cigarette smoke increases susceptibility to 
viral infections possibly via alteration/inhibition of immune 
response (Robbins et al 2004).
Another possible mechanism leading to increased sus-
ceptibility is related to up regulation of ICAM-1, the receptor 
for the major group of human rhinoviruses. Latent expres-
sion of adenoviral E1A protein in alveolar epithelial cells of 
patients with emphysema increases ICAM-1 expression and 
this could be a potential mechanism for greater susceptibility 
to rhinovirus infection in COPD (Retamales et al 2001).
Patients with COPD are chronically colonized with 
airway bacteria, and the bacterial load is related to airway 
inﬂ  ammation and disease progression (Patel et al 2002). It has 
been postulated that bacterial colonization could contribute 
to increased susceptibility to viral infection in COPD patients 
for example by increasing ICAM-1 expression in bronchial 
epithelial cells either directly or through induced inﬂ  amma-
tion (Sajjan et al 2006).
Further studies are required to investigate the interaction 
between chronic bacterial colonization and respiratory viral 
infection and in particular whether chronic bacterial coloniza-
tion can increase susceptibility to viral infection or vice versa.
Mechanisms of rhinovirus and 
respiratory syncytial virus-induced 
COPD exacerbations
As the contribution of viruses to COPD exacerbations has 
only recently been appreciated little research has been 
carried out into the mechanisms of virus-induced inﬂ  am-
mation. Performing airway sampling at exacerbation in 
COPD patients is even more difﬁ  cult than in asthmatics due 
to their older age and high prevalence of co-morbidities. 
One way to overcome these obstacles is the development 
of a human experimental model that would allow studies 
to take place under controlled conditions. The ﬁ  rst step 
towards development of such a model has been recently 
realized with the reporting of the ﬁ  rst study evaluating the 
effects of an experimental viral infection in COPD patients 
(Mallia et al 2006).
COPD exacerbations are associated with an increased 
numbers of inflammatory cells in the lower airways 
and increased/decreased release of pro-inflammatory/
anti-inﬂ  ammatory mediators (Wedzicha and Donaldson 
2003). Through these mechanisms respiratory viral infec-
tions may enhance the pathological processes associated with 
cigarette smoking and contribute to the lung pathology and 
loss of lung function associated with COPD. The type and 
the degree of activation of the different inﬂ  ammatory cells 
recruited to the lung during COPD exacerbations has not 
been well studied (Zhu et al 2001; Qiu et al 2003).
Cells and molecules involved 
in respiratory virus-driven 
airway inﬂ  ammation in COPD 
exacerbations
Despite growing clinical evidence for a role of respiratory 
viral infections in the pathogenesis of COPD exacerbations, 
the precise mechanisms of respiratory virus-induced airway 
inﬂ  ammation and of host defenses against respiratory viruses 
are poorly understood (Johnston 2005).
Most of the data available relate to rhinovirus (RV) and respi-
ratory syncytial virus (RSV), ie, the respiratory viruses that appear 
to be more frequently involved in COPD exacerbations.
Rhinovirus
Human rhinoviruses (RV) are the largest genus in the 
Picornaviridae family. They are single-stranded RNA viruses. 
Rhinovirus is the main cause of the common cold and several 
studies supported the role of this pathogen in both asthma and 
COPD exacerbations. Recent data documents that rhinovirus 
can reach and replicate in the lower airways.
There is striking genetic diversity of the RV strains circu-
lating in a given community during a short time (Oliveira et al 
1993). Rhinovirus serotypes are divided into two groups on 
the basis of receptor speciﬁ  city. The “major” receptor group 
(including RV14 and RV16) utilizes intercellular adhesion 
molecule-1 [(ICAM-1); CD54] as a receptor for infecting the 
target cells (Greve et al 1989; Terajima et al 1997). Using 
ICAM-1, RV can infect airway epithelial cells, but there is 
little evidence of productive replication in other cells such as 
monocytes, macrophages and eosinophils granulocytes. The 
“minor” receptor group, do not bind ICAM-1 and instead bind 
the LDL receptor and related proteins (Hofer et al 1994).
Rhinovirus is transmitted by aerosol through infectious 
droplet nuclei emanating from infected subjects (Myatt et al 
2003; Samet 2004).
Respiratory syncytial virus
Respiratory syncytial virus (RSV) is a member of the family 
Paramyxoviridae, subfamily Pneumovirus; it is an enveloped 
RNA virus with a negative-sense, nonsegmented, single-
stranded RNA genome.
RSV is a major respiratory pathogen, it is most common in 
infants where it causes a range of illnesses from asymptomatic 
infection through upper respiratory tract infection, bronchiolitis, International Journal of COPD 2007:2(4) 480
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and pneumonia (Falsey and Walsh 2000; Hall 2001; Falsey 
et al 2005). In addition, during the past two decades, a growing 
number of studies have clearly established RSV as a severe 
pathogen in certain adult populations. The elderly, those with 
underlying cardiopulmonary disease (chronic heart failure, 
chronic obstructive pulmonary disease, bronchial asthma) 
and the immunocompromised patients appear to be at greatest 
risk of developing severe, even life-threatening lung disease 
following RSV infection (Hall 2000; Walsh and Falsey 2004; 
Falsey 2005; Sethi and Murphy 2005).
The primary site of RSV replication are the airway epithe-
lial cells, whereas other cell types (monocytes/macrophages, 
airway smooth muscle cells eosinophils, neutrophils, mast 
cells, dendritic cells and endothelial cells) are targets of abor-
tive replication or viral attachment only (Arnold and Konig 
2005; de Graaff et al 2005; Guerrero-Plata et al 2006).
In human bronchial epithelial cells RSV colocalize with 
ICAM-1, and this binding can be inhibited by an antibody 
to the fusion F protein. These data suggests that RSV inter-
action with ICAM-1 involves the F protein and facilitates 
RSV entry and infection of human bronchial epithelial cells 
(Behera et al 2001). Interestingly in vitro RSV infection of 
human lung endothelial cells increase their expression of 
ICAM-1 (Arnold and Konig 2005).
Since RSV replication is largely restricted to airway 
epithelial cells, an hypothesis is that inﬂ  ammatory cell 
recruitment by the infected cells will start the later immu-
nopathology (Becker et al 1992; Becker and Soukup 1999). 
The effects of RSV on airway inﬂ  ammation may be therefore 
partly mediated by sequential production of pro-inﬂ  ammatory 
cytokines/chemokines in the infected airway epithelium.
Respiratory viruses and 
transcription factors
The activation of several nuclear factors has recently been studied 
in COPD (Caramori 2004). Several studies have shown that both 
the promoter genomic regions and the related transcription fac-
tors that regulate inﬂ  ammatory mediator production are deeply 
affected by respiratory virus infection. Most of the data published 
until now on this issue are mainly related to rhinovirus and 
respiratory syncytial virus infections. More research is required 
to clarify the molecular events that determine the changes in gene 
transcription determined by virus infection in target cells.
Molecular mechanisms of rhinovirus 
induced inﬂ  ammation
To date the speciﬁ  c molecular mechanisms involved in the 
production of pro-inﬂ  ammatory mediators by bronchial/lung 
cells after rhinovirus infection are still not fully characterized. 
However, some studies have examined at the molecular level the 
transcription factors involved in RV-induced production of pro-
inﬂ  ammatory mediators from structural cells of the lungs.
Rhinovirus infection of primary bronchial epithelial cells 
induces a rapid increase of intracellular oxidants (superoxide 
anion) production that is maximal at the time of nuclear fac-
tor κB (NF-κB) activation. Intriguingly, it has been shown, 
in the same model, that reducing agents inhibit RV-induced 
ICAM-1 up-regulation, ICAM-1 promoter activation and 
NF-κB activation (Papi et al 2002). This data suggests that 
modulation of RV induced intracellular oxidant burst can 
be a novel pharmacological approach to treat/prevent RV 
induced COPD exacerbations.
Several transcription factors appear to be activated 
after rhinovirus infection on a variety of respiratory cells 
(Caramori 2006). These proteins include NF-κB, AP-1 and 
GATA families. Activation of intracellular signaling path-
ways is induced by rhinovirus in epithelial cells, which may 
be dependent on surface receptor binding (ICAM-1), or by 
intracellular products during viral replication such as double-
stranded RNA (dsRNA). It has been shown that dsRNA can 
activate components of several signaling pathways including 
protein kinase R, nuclear factor-κB (NF-κB) and p38 mitoge-
nactivated protein kinase (MAPK) (Alexopoulou et al 2001). 
However, to date, no studies have investigated the role of 
these molecules in rhinovirus infection.
Rhinovirus-induced activation of NF-κB leads to an 
increased expression of proinﬂ  ammatory cytokines (IL-1, 
IL-6, granulocyte colony-stimulating factor (G-CSF) and 
GM-CSF), CXC chemokines (IL-8) and ICAM-1 (Papi and 
Johnston 1999b), whereas expression of VCAM-1 seems to be 
mediated by the activation of both NF-κB and GATA proteins 
(Papi and Johnston 1999a). It has been recently suggested 
that early activation of p38 MAPK pathway by rhinovirus 
infection, which induces the activation of many transcription 
factors, could be a key event in the regulation of rhinovirus-
induced cytokine transcription, and may provide a new target 
for inhibition of rhinovirusinduced asthma exacerbations.
Molecular mechanisms of 
respiratory syncytial virus induced 
inﬂ  ammation
RSV-induced cytokine production in airway epithelial cells 
seems to play an important role in the pathogenesis of RSV 
respiratory tract infections.
Recent studies on RSV-epithelial cell interactions have 
demonstrated that RSV can act at the molecular level by altering International Journal of COPD 2007:2(4) 481
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cytokine gene transcription (Jamaluddin et al 1998; Mastronarde 
et al 1998) or mRNA stability (Koga et al 1999).
As for RV it has been shown that early activation 
of mitogen-activated protein kinases (MAPKs) by RSV 
infection is a key event in the regulation of RSV-induced 
pro-inflammatory transcription factors activation and 
cytokine/chemokines transcription in bronchial epithelial 
cells, however both p38 MAP kinase, mitogen-activated 
protein kinase kinase kinase 14/ NF-κB-inducing kinase 
(MAP3K14/NIK) and extracellular signal-regulated kinases 
(ERKs) pathways seem to be important (Chen et al 2000; 
Kong et al 2004; Chouldhary et al 2005; Rixon et al 2005).
Several transcription factors appear to be activated after 
RSV infection on a variety of respiratory cells. These pro-
teins include mainly the NF-κB and AP-1 families. NF-κB 
is activated by the M2-1 protein of RSV (Fiedler et al 1996; 
Mastronarde 1998; Casola et al 2000; Chouldhary 2005; 
Reimers et al 2005; Spann et al 2005).
Link between virus infection, type of 
inﬂ  ammation, dyspnea and sputum 
purulence
The mechanisms by which virus-enhanced inﬂ  ammation may 
pave the way to COPD exacerbations are so far unknown. The 
recent availability of a human model of RV-induced COPD 
exacerbations (Mallia et al 2007) will foster the research and 
the progress in this important area. In COPD this is so far 
the only model where a speciﬁ  c etiology has been experi-
mentally proven to induce exacerbation. In this pilot study 
mild to moderate COPD patients were safely experimentally 
infected with rhinovirus providing for the ﬁ  st time that, 
in in vivo experimental condition, rhinovirus infection in 
COPD patients is per se sufﬁ  cient to trigger exacerbations. 
Lower respiratory tract symptom scores were signiﬁ  cantly 
increased compared to baseline on days 7 to 14, with peak 
lower respiratory tract symptoms on days 10 and 11. When 
the individual symptoms were analyzed separately, all ﬁ  ve 
lower respiratory symptom domains (wheeze, cough, sputum 
production and dyspnea) increased from baseline however 
the increases were only statistically signiﬁ  cant for wheeze, 
cough and sputum production, but not for dyspnea. In terms 
of recovery, all symptom domains other than sputum pro-
duction had recovered to baseline by day 20, however full 
recovery of sputum production took almost 4 weeks (Mallia 
et al 2006). This important data suggests that the link between 
virus-induced COPD exacerbation and increased dyspnea 
and sputum production is probably very complex and needs 
dedicated studies for a better comprehension.
Intriguingly, it has been recently shown that viral induced 
severe COPD exacerbations with or without concomitant 
bacterial infection are characteristically associated with 
sputum eosinophilia whereas sputum neutrophilia is present 
during exacerbations in all subgroups independently 
from etiology (Papi et al 2006). This ﬁ  nding is in line 
with previous studies showing that in vivo experimental 
rhinovirus infection in normal subjects leads to lower 
airway eosinophilia (Fraenkel et al 1995). Thus, enhanced 
airway eosinophilic inﬂ  ammation of the airway may be a 
hallmark of viral infection. Further studies are required to 
conﬁ  rm and extend this pivotal observation and to evalu-
ate whether modulation of rhinovirus-induced activation 
of pro-inﬂ  ammatory mediators (ie, NF-κB) might be of 
any relevance in the treatment/prevention of virus-induced 
COPD exacerbations.
Conclusions
Many studies conducted in the last decade have produced 
convincing data on the molecular mechanisms involved in the 
pathogenesis of natural and experimental respiratory virus infec-
tions in humans, particularly rhinovirus (RV) and respiratory 
syncytial virus (RSV). Most of the studies have been performed 
on human respiratory epithelial cells, which can be directly 
infected by RV and RSV. Their infection by RV and RSV 
determines the production of several pro-inﬂ  ammatory mol-
ecules (such as cytokines, chemokines and adhesion molecules). 
Conversely, very few studies have been conducted in vivo on 
the molecular mechanisms underlying the pro-inﬂ  ammatory 
derangement induced by respiratory viruses in the airways dur-
ing COPD exacerbations. Collectively these studies suggest a 
critical role for several transcription factor families, including 
the NF-κB, AP-1 and GATA families, in the production of 
pro-inﬂ  ammatory mediators after RV and RSV infection. The 
relative importance of each cell, mediator, signalling pathway 
and transcription factor will hopefully be clariﬁ  ed in the next 
few years. The recent development of the ﬁ  rst human model of 
virus induced COPD exacerbation, that has been demonstrated 
to be feasible and so far, safe, will facilitate identiﬁ  cation of 
novel pharmacological targets that will provide opportunities 
to develop new treatments for exacerbations of COPD.
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